logo
Plus   Neg
Share
Email

Genome Signs Deal With Merck KGaA And Pfizer For Immuno-oncology Microbiome Study

Genome and Company said that it has expanded collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric cancers.

The objective of the clinical trial or "Study 201" is to investigate the efficacy and safety of the combination of GEN-001 and avelumab for gastric and gastroesophageal junction adenocarcinoma that continue to be difficult to treat. The trial will be conducted simultaneously at six or more hospital and medical center sites in the Republic of Korea.

Genome said it will proceed with Phase 2a to assess the efficacy and safety of the combination of GEN-001 and avelumab using the defined recommended phase 2 dose (RP2D) of GEN-001 in combination with avelumab.

Merck KGaA, Darmstadt, Germany and Pfizer will supply avelumab for use in the new company-led clinical trial, Study 201.

Genome noted that t he extended clinical collaboration between Genome and Company and Merck KGaA, Darmstadt, Germany and Pfizer marks the first time that two consecutive clinical development collaborations have been executed between combination partners for immuno-oncology microbiome treatment.

As per the terms of the agreements, Genome will be the sponsor of the studies, and Merck KGaA, Darmstadt, Germany and Pfizer will supply avelumab for both Study 101 and Study 201. Both parties will have access to the clinical data.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
Follow RTT